Bioverativ Stock Price, News & Analysis (NASDAQ:BIVV)

$104.30 +0.39 (+0.38 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$103.91
Today's Range$104.05 - $104.43
52-Week Range$48.14 - $104.43
Volume760,527 shs
Average Volume2.92 million shs
Market Capitalization$11.23 billion
P/E Ratio31.68
Dividend YieldN/A
BetaN/A

About Bioverativ (NASDAQ:BIVV)

Bioverativ logoBioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive BIVV News and Ratings via Email

Sign-up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIVV
CUSIPN/A
Phone781-663-4400

Debt

Debt-to-Equity RatioN/A
Current Ratio2.00%
Quick Ratio1.89%

Price-To-Earnings

Trailing P/E Ratio31.679974634069
Forward P/E Ratio27.23
P/E Growth1.94

Sales & Book Value

Annual Sales$1.17 billion
Price / Sales9.66
Cash Flow$2.89 per share
Price / Cash36.10
Book Value$8.29 per share
Price / Book12.58

Profitability

Trailing EPS$3.28
Net Income$355.60 million
Net Margins30.43%
Return on Equity40.99%
Return on Assets22.79%

Miscellaneous

Employees460
Outstanding Shares108,220,000

Bioverativ (NASDAQ:BIVV) Frequently Asked Questions

What is Bioverativ's stock symbol?

Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."

How were Bioverativ's earnings last quarter?

Bioverativ Inc (NASDAQ:BIVV) issued its earnings results on Thursday, October, 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.25. The biotechnology company had revenue of $291.60 million for the quarter, compared to analysts' expectations of $285.45 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. The business's revenue was up 27.2% compared to the same quarter last year. View Bioverativ's Earnings History.

When will Bioverativ make its next earnings announcement?

Bioverativ is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Bioverativ.

Where is Bioverativ's stock going? Where will Bioverativ's stock price be in 2018?

16 brokers have issued 1-year price objectives for Bioverativ's shares. Their forecasts range from $47.00 to $80.00. On average, they expect Bioverativ's stock price to reach $63.25 in the next twelve months. View Analyst Ratings for Bioverativ.

What are Wall Street analysts saying about Bioverativ stock?

Here are some recent quotes from research analysts about Bioverativ stock:

  • 1. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (1/8/2018)
  • 2. Cowen Inc analysts commented, "Bioverativ reported Q2 revenue of $289MM (+38% Y/Y) versus consensus of." (8/4/2017)

Are investors shorting Bioverativ?

Bioverativ saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 2,299,449 shares, a decline of 76.0% from the January 12th total of 9,599,274 shares. Based on an average daily trading volume, of 5,194,755 shares, the short-interest ratio is currently 0.4 days. Approximately 2.2% of the shares of the stock are short sold.

Who are some of Bioverativ's key competitors?

Who are Bioverativ's key executives?

Bioverativ's management team includes the folowing people:

  • Brian S. Posner, Independent Chairman of the Board (Age 55)
  • John G. Cox, Chief Executive Officer, Director (Age 54)
  • John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
  • Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
  • Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
  • Richard Brudnick, Executive Vice President - Business Development (Age 60)
  • Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
  • Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
  • Alexander J. Denner Ph.D., Independent Director (Age 47)
  • Louis J. Paglia, Independent Director (Age 59)

Who owns Bioverativ stock?

Bioverativ's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.02%), Clearbridge Investments LLC (3.51%), HealthCor Management L.P. (3.47%), Old Mutual Global Investors UK Ltd. (2.32%), Jackson Square Partners LLC (1.95%) and Woodford Investment Management Ltd (1.80%). Company insiders that own Bioverativ stock include Alexander J Denner, Brian S Posner, Diantha Duvall and Louis J Paglia. View Institutional Ownership Trends for Bioverativ.

Who sold Bioverativ stock? Who is selling Bioverativ stock?

Bioverativ's stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, American Century Companies Inc., Renaissance Technologies LLC, Wells Fargo & Company MN, HealthCor Management L.P., Arrowstreet Capital Limited Partnership, Franklin Resources Inc. and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Bioverativ.

Who bought Bioverativ stock? Who is buying Bioverativ stock?

Bioverativ's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., OppenheimerFunds Inc., Old Mutual Global Investors UK Ltd., APG Asset Management N.V., Acadian Asset Management LLC, Jackson Square Partners LLC, Two Sigma Investments LP and Bank of New York Mellon Corp. Company insiders that have bought Bioverativ stock in the last two years include Alexander J Denner, Brian S Posner and Louis J Paglia. View Insider Buying and Selling for Bioverativ.

How do I buy Bioverativ stock?

Shares of Bioverativ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioverativ's stock price today?

One share of Bioverativ stock can currently be purchased for approximately $104.30.

How big of a company is Bioverativ?

Bioverativ has a market capitalization of $11.23 billion and generates $1.17 billion in revenue each year. The biotechnology company earns $355.60 million in net income (profit) each year or $3.28 on an earnings per share basis. Bioverativ employs 460 workers across the globe.

How can I contact Bioverativ?

Bioverativ's mailing address is 225 2ND AVENUE, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-663-4400 or via email at [email protected]


MarketBeat Community Rating for Bioverativ (BIVV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bioverativ (NASDAQ:BIVV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.192.252.442.40
Ratings Breakdown: 0 Sell Rating(s)
13 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $63.25$62.57$60.36$59.46
Price Target Upside: 38.69% downside39.71% downside18.91% upside3.99% upside

Bioverativ (NASDAQ:BIVV) Consensus Price Target History

Price Target History for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ:BIVV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018ArgusReiterated RatingBuy -> HoldLowView Rating Details
1/24/2018Credit Suisse GroupReiterated RatingNeutral -> NeutralLowView Rating Details
1/23/2018Raymond James FinancialDowngradeStrong-Buy -> HoldLowView Rating Details
1/23/2018Morgan StanleyUpgradeUnderweight -> Equal WeightLowView Rating Details
1/22/2018Jefferies GroupDowngradeBuy -> HoldLowView Rating Details
1/22/2018Piper Jaffray CompaniesDowngradeOverweight -> NeutralLowView Rating Details
1/18/2018Royal Bank of CanadaBoost Price TargetMarket Perform$68.00LowView Rating Details
11/20/2017Deutsche BankSet Price TargetHold$53.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$58.00HighView Rating Details
8/4/2017CowenReiterated RatingBuy$80.00HighView Rating Details
6/28/2017William BlairInitiated CoverageMkt Perform -> Market PerformLowView Rating Details
6/28/2017WedbushReiterated RatingMarket PerformLowView Rating Details
4/24/2017GabelliDowngradeBuy -> HoldLowView Rating Details
3/28/2017Leerink SwannSet Price TargetBuy$62.00LowView Rating Details
3/27/2017Stifel NicolausBoost Price TargetBuy -> Buy$54.00 -> $57.00LowView Rating Details
3/13/2017Goldman Sachs GroupDowngradeBuy -> Neutral$55.00MediumView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Bioverativ (NASDAQ:BIVV) Earnings History and Estimates Chart

Earnings by Quarter for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ BIVV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018        
10/26/2017Q3 2017$0.55$0.80$285.45 million$291.60 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.71$0.88$269.00 million$289.10 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.62$0.65ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bioverativ (NASDAQ:BIVV) Earnings Estimates

Current Year EPS Consensus Estimate: $3.83 EPS
Next Year EPS Consensus Estimate: $4.03 EPS

Dividends

Dividend History for Bioverativ (NASDAQ:BIVV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bioverativ (NASDAQ BIVV) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 99.97%
Insider Trades by Quarter for Bioverativ (NASDAQ:BIVV)
Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Bioverativ (NASDAQ BIVV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2017Brian S PosnerDirectorBuy1,000$59.19$59,190.006,693View SEC Filing  
8/7/2017Louis J PagliaDirectorBuy2,000$59.70$119,400.005,056View SEC Filing  
6/28/2017Diantha DuvallInsiderSell818$60.47$49,464.462,128View SEC Filing  
5/30/2017Alexander J DennerDirectorBuy90,000$55.93$5,033,700.005,001View SEC Filing  
5/26/2017Louis J PagliaDirectorBuy2,000$57.76$115,520.003,056View SEC Filing  
5/24/2017Brian S PosnerDirectorBuy2,000$53.86$107,720.004,993View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bioverativ (NASDAQ BIVV) News Headlines

Source:
DateHeadline
 Analysts Expect Bioverativ Inc (BIVV) Will Post Quarterly Sales of $333.33 Million Analysts Expect Bioverativ Inc (BIVV) Will Post Quarterly Sales of $333.33 Million
www.americanbankingnews.com - February 18 at 5:46 AM
Bioverativ Inc (BIVV) Files 10-K for the Fiscal Year Ended on December 31, 2017Bioverativ Inc (BIVV) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 15 at 8:27 AM
Abiomeds Extended FDA Nod for Impella Boosts Women HealthAbiomed's Extended FDA Nod for Impella Boosts Women Health
finance.yahoo.com - February 14 at 5:03 PM
Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia AHaemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A
finance.yahoo.com - February 14 at 9:26 AM
Bioverativ Reports Fourth Quarter and Full Year 2017 PerformanceBioverativ Reports Fourth Quarter and Full Year 2017 Performance
finance.yahoo.com - February 14 at 9:26 AM
Bioverativ (BIVV) Releases Quarterly  Earnings Results, Beats Expectations By $0.73 EPSBioverativ (BIVV) Releases Quarterly Earnings Results, Beats Expectations By $0.73 EPS
www.americanbankingnews.com - February 13 at 7:08 PM
[$$] 3 Biotechs That Could Benefit From an M&A Frenzy[$$] 3 Biotechs That Could Benefit From an M&A Frenzy
finance.yahoo.com - February 13 at 4:10 PM
Bioverativ Inc (BIVV) Receives Average Rating of "Hold" from BrokeragesBioverativ Inc (BIVV) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 10 at 9:44 AM
Bioverativ Inc (BIVV) Sees Significant Drop in Short InterestBioverativ Inc (BIVV) Sees Significant Drop in Short Interest
www.americanbankingnews.com - February 10 at 2:02 AM
ACT NOW: Monteverde & Associates PC Announces an Investigation of Bioverativ Inc. - BIVVACT NOW: Monteverde & Associates PC Announces an Investigation of Bioverativ Inc. - BIVV
finance.yahoo.com - February 8 at 4:08 PM
Sanofi: Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.Sanofi: Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
www.finanznachrichten.de - February 8 at 8:40 AM
Biotech, Pharma Stocks Tumble Amid Big Market Sell-OffBiotech, Pharma Stocks Tumble Amid Big Market Sell-Off
finance.yahoo.com - February 6 at 9:24 AM
Bioverativ (BIVV) Set to Announce Earnings on TuesdayBioverativ (BIVV) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - February 6 at 4:20 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Into Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders - BIVVSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Into Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders - BIVV
finance.yahoo.com - February 1 at 4:09 PM
Bioverativ Inc (BIVV) Expected to Post Quarterly Sales of $325.89 MillionBioverativ Inc (BIVV) Expected to Post Quarterly Sales of $325.89 Million
www.americanbankingnews.com - February 1 at 5:56 AM
Zacks: Analysts Anticipate Bioverativ Inc (BIVV) to Post $0.89 Earnings Per ShareZacks: Analysts Anticipate Bioverativ Inc (BIVV) to Post $0.89 Earnings Per Share
www.americanbankingnews.com - January 30 at 7:32 AM
Bioverativ (BIVV) Stock Rating Reaffirmed by Credit Suisse GroupBioverativ (BIVV) Stock Rating Reaffirmed by Credit Suisse Group
www.americanbankingnews.com - January 28 at 3:28 PM
Bioverativ (BIVV) Rating Reiterated by ArgusBioverativ (BIVV) Rating Reiterated by Argus
www.americanbankingnews.com - January 28 at 2:54 PM
Stock Traders Purchase Large Volume of Put Options on Bioverativ (BIVV)Stock Traders Purchase Large Volume of Put Options on Bioverativ (BIVV)
www.americanbankingnews.com - January 26 at 1:40 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to ShareholdersINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders
finance.yahoo.com - January 24 at 4:25 PM
WeissLaw LLP Investigates Bioverativ Inc. AcquisitionWeissLaw LLP Investigates Bioverativ Inc. Acquisition
finance.yahoo.com - January 24 at 4:25 PM
William Blair Weighs in on Bioverativ Incs FY2017 Earnings (BIVV)William Blair Weighs in on Bioverativ Inc's FY2017 Earnings (BIVV)
www.americanbankingnews.com - January 24 at 7:36 AM
Bioverativs (BIVV) Quant Score Gives it Buy | InvestorPlace - Investorplace.comBioverativ's (BIVV) Quant Score Gives it Buy | InvestorPlace - Investorplace.com
investorplace.com - January 24 at 6:35 AM
Genzyme Corporation -- Moodys affirms Sanofis A1 ratings following Bioverativ acquisitionGenzyme Corporation -- Moody's affirms Sanofi's A1 ratings following Bioverativ acquisition
finance.yahoo.com - January 24 at 6:35 AM
Bragar Eagel & Squire, PC is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of ... - Business Wire (press release)Bragar Eagel & Squire, PC is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of ... - Business Wire (press release)
www.businesswire.com - January 23 at 3:03 PM
Pharma M&A Picks Up Momentum - BenzingaPharma M&A Picks Up Momentum - Benzinga
www.benzinga.com - January 23 at 3:03 PM
Two drug companies are exploding after a pair of biotech mega-deals - Business InsiderTwo drug companies are exploding after a pair of biotech mega-deals - Business Insider
www.businessinsider.com - January 23 at 3:03 PM
Bioverativ Reaches Analyst Target Price - NasdaqBioverativ Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - January 23 at 3:03 PM
Bioverativs Shareholders Hit The Jackpot - Seeking AlphaBioverativ's Shareholders Hit The Jackpot - Seeking Alpha
seekingalpha.com - January 23 at 3:03 PM
Bioverativ (BIVV) Cut to "Hold" at Jefferies GroupBioverativ (BIVV) Cut to "Hold" at Jefferies Group
www.americanbankingnews.com - January 22 at 8:34 PM
Bioverativ (BIVV) Cut to "Neutral" at Piper Jaffray CompaniesBioverativ (BIVV) Cut to "Neutral" at Piper Jaffray Companies
www.americanbankingnews.com - January 22 at 4:22 PM
Bioverativ Inc. (BIVV) Has Soared To A New High After Bought By SanofiBioverativ Inc. (BIVV) Has Soared To A New High After Bought By Sanofi
www.nasdaq.com - January 22 at 3:40 PM
Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
www.streetinsider.com - January 22 at 3:40 PM
Sanofi near deal to buy Bioverativ for more than $11.5 billion: WSJSanofi near deal to buy Bioverativ for more than $11.5 billion: WSJ
www.reuters.com - January 22 at 3:40 PM
Sanofi to Buy Hemophilia Drugmaker Bioverativ for Over $11.5 BillionSanofi to Buy Hemophilia Drugmaker Bioverativ for Over $11.5 Billion
www.wsj.com - January 22 at 3:40 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders – BIVVSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders – BIVV
finance.yahoo.com - January 22 at 3:40 PM
Biotech ETF rallies on merger news, on track for highest close since 2015Biotech ETF rallies on merger news, on track for highest close since 2015
finance.yahoo.com - January 22 at 3:40 PM
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - January 22 at 3:40 PM
BIOVERATIV INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BuyoutBIOVERATIV INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - January 22 at 3:40 PM
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Bioverativ Inc.ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Bioverativ Inc.
finance.yahoo.com - January 22 at 3:40 PM
Bioverativ Inc Stock Gets 64% Premium in Acquisition by SanofiBioverativ Inc Stock Gets 64% Premium in Acquisition by Sanofi
investorplace.com - January 22 at 5:49 AM
Sanofi to Acquire Bioverativ for $11.6 BillionSanofi to Acquire Bioverativ for $11.6 Billion
feeds.benzinga.com - January 22 at 3:45 AM
Bioverativ (BIVV) Price Target Raised to $68.00 at Royal Bank of CanadaBioverativ (BIVV) Price Target Raised to $68.00 at Royal Bank of Canada
www.americanbankingnews.com - January 18 at 12:58 PM
Bioverativ to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018Bioverativ to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018
finance.yahoo.com - January 16 at 4:58 PM
Bioverativ Inc (BIVV) Receives Average Rating of "Hold" from AnalystsBioverativ Inc (BIVV) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 16 at 8:00 AM
 Analysts Anticipate Bioverativ Inc (BIVV) Will Announce Quarterly Sales of $308.45 Million Analysts Anticipate Bioverativ Inc (BIVV) Will Announce Quarterly Sales of $308.45 Million
www.americanbankingnews.com - January 15 at 10:04 PM
Bioverativ Inc (BIVV) PT Raised to $100 at Cowen - StreetInsider.com - StreetInsider.comBioverativ Inc (BIVV) PT Raised to $100 at Cowen - StreetInsider.com - StreetInsider.com
www.streetinsider.com - January 10 at 9:58 AM
Pre-Open Movers 01/09: (ATUS) (PSTI) (GBT) Higher; (AXSM) (BGFV) (D) Lower (more...)Pre-Open Movers 01/09: (ATUS) (PSTI) (GBT) Higher; (AXSM) (BGFV) (D) Lower (more...)
www.streetinsider.com - January 9 at 5:03 PM
Bioverativ (BIVV) Upgraded by Zacks Investment Research to BuyBioverativ (BIVV) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - January 8 at 7:52 PM
Bioverativ (BIVV) Cut to "Hold" at Zacks Investment ResearchBioverativ (BIVV) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 3 at 5:40 PM

SEC Filings

Bioverativ (NASDAQ:BIVV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bioverativ (NASDAQ:BIVV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bioverativ (NASDAQ BIVV) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.